4610 Federal Register / Vol. 89, No. 16 / Wednesday, January 24, 2024 / Notices 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Heart, Lung, and 

Blood Initial Review Group; NHLBI 

Mentored Patient-Oriented Research Study 

Section. 

Date: February 29–March 1, 2024. 

Time: 9:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge I, 6705 Rockledge Drive, Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: Fungai Chanetsa, Ph.D., 

MPH, Scientific Review Officer, Office of 

Scientific Review/DERA, National Heart, 

Lung, and Blood Institute, National Institutes 

of Health, 6705 Rockledge Drive, Room 206– 

B, Bethesda, MD 20817, (301) 402–9394, 

fungai.chanetsa@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: January 18, 2024. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–01296 Filed 1–23–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: Ben 

Hurley at 240–669–5092, or 

benjamin.hurley@nih.gov. Licensing 

information may be obtained by 

communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852: tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Hybridoma Cell Lines 2A4 and 5B12 

Against Puromycin Description of 

Technology 

Protein translation is a central cellular 

function attracting increasing attention 

from cell biologists as they integrate 

gene product specific information into a 

systems view of cellular function. 

Scientists at NIAID developed the 

puromycin-specific antibodies that 

allow for the specific detection of 

puromycin-containing nascent 

polypeptides via standard 

immunofluorescence or flow cytometry. 

The resulting ribopuromycylation 

method (RPM) localizes translation in 

cells and can be applied to any PMYsensitive eukaryotic or prokaryotic cell 

to study the dynamics of protein 

synthesis at the cellular level and 

investigate translational processes. It 

can also be used in vitro or in vivo to 

measure the number of translating 

ribosomes using flow cytometry. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications: 

• Broad application for studying protein 

translation. 

Competitive Advantages: 

• This technology generates antibodies 

specific for puromycin that can be 

used to localize translating ribosomes 

in all cell types. 

Development Stage: 

• Research Materials 

Inventors: Jonathan Yewdell, MD, 

Ph.D., Alexandre David, Ph.D., both of 

NIAID. 

Publications: David A. Dolan BP, 

Hickman HD, Knowlton JJ, Clavarino G, 

Pierre P, Bennink JR, Yewdell JW. 

Nuclear translation visualized by 

ribosome-bound nascent chain 

puromycylation. J Cell Biol. 2012 Apr 

2;197(1):45–57. doi: 10.1083/ 

jcb.201112145. PMID: 22472439; 

PMCID: PMC3317795. 

Also: PMID 29552591, 27385780, 

25311127, 23229864. 

Intellectual Property: HHS Reference 

No. E–003–2021. 

Licensing Contact: To license this 

technology, please contact Ben Hurley 

at 240–669–5092, or benjamin.hurley@

nih.gov, and reference E–003–2021. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. For 

collaboration opportunities, please 

contact Ben Hurley at 240–669–5092, or 

benjamin.hurley@nih.gov. 

Dated: January 19, 2024. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2024–01364 Filed 1–23–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Biobehavioral Processes. 

Date: February 15, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jeanne M. McCaffery, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, 301–594–3854, jeanne.mccaffery@

nih.gov. 

Name of Committee: Biological Chemistry 

and Macromolecular Biophysics Integrated 

Review Group; Chemical Biology and Probes 

Study Section. 

Date: February 15–16, 2024. 

Time: 10:00 a.m. to 8:30 p.m. 

Agenda: To review and evaluate grant 

applications. 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 16 / Wednesday, January 24, 2024 / Notices 4611 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Michael Eissenstat, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4166, 

MSC 7806, Bethesda, MD 20892, (301) 435– 

1722, eissenstatma@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; AcademicIndustrial Partnerships for Translation of 

Technologies. 

Date: February 15–16, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jennifer Ann Sanders, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 496–3553, jennifer.sanders@

nih.gov. 

Name of Committee: Genes, Genomes, and 

Genetics Integrated Review Group; Genetic 

Variation and Evolution Study Section. 

Date: February 15–16, 2024. 

Time: 10:00 a.m. to 8:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Hybrid Meeting). 

Contact Person: Guoqin Yu, Ph.D,. 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 435–1276, guoqin.yu@nih.gov. 

Name of Committee: Population Sciences 

and Epidemiology Integrated Review Group; 

Social Sciences and Population Studies B 

Study Section. 

Date: February 15–16, 2024. 

Time: 10:30 a.m. to 9:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Kate Fothergill, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3142, 

Bethesda, MD 20892, 301–435–2309, 

fothergillke@mail.nih.gov. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience 

Integrated Review Group; Neurobiology of 

Pain and Itch Study Section. 

Date: February 20–21, 2024. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Anne-Sophie Marie Lucie 

Wattiez, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Bethesda, MD 20892, (301) 594–4642, annesophie.wattiez@nih.gov. 

Name of Committee: Healthcare Delivery 

and Methodologies Integrated Review Group 

Health Promotion in Communities Study 

Section. 

Date: February 20–21, 2024. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Helena Eryam Dagadu, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3137, 

Bethesda, MD 20892, (301) 435–1266, 

dagaduhe@csr.nih.gov. 

Name of Committee: Applied Immunology 

and Disease Control Integrated Review 

Group; Transmission of Vector-Borne and 

Zoonotic Diseases Study Section. 

Date: February 20–21, 2024. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Haruhiko Murata, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, 301–594–3245, muratah@csr.nih.gov. 

Name of Committee: Biology of 

Development and Aging Integrated Review 

Group; Mechanisms of Cancer Therapeutics 

A Study Section. 

Date: February 20–21, 2024. 

Time: 9:00 a.m. to 8:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Careen K. Tang-Toth, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6214, 

MSC 7804, Bethesda, MD 20892, (301)435– 

3504, tothct@csr.nih.gov. 

Name of Committee: Oncology 1—Basic 

Translational Integrated Review Group; 

Cancer Genetics Study Section. 

Date: February 20–21, 2024. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Juraj Bies, Ph.D., Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 4158, MSC 7806, Bethesda, MD 

20892, 301 435 1256, biesj@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: January 18, 2024. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–01290 Filed 1–23–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Heart, Lung, and 

Blood Initial Review Group; NHLBI SingleSite and Pilot Clinical Trials Study Section. 

Date: February 28–29, 2024. 

Time: 8:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge I, 6705 Rockledge Drive, Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: YingYing Li-Smerin, MD, 

Ph.D., Scientific Review Officer, Office of 

Scientific Review/DERA, National Heart, 

Lung, and Blood Institute, 6705 Rockledge 

Drive, Room 207–P, Bethesda, MD 20892– 

7924, 301–827–7942, lismerin@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: January 18, 2024. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–01295 Filed 1–23–24; 8:45 am] 

BILLING CODE 4140–01–P 


ddrumheller on DSK120RN23PROD with NOTICES1